Bone Marrow Transplantation with Intensive Combination Chemotherapy/Radiation Therapy (SCARI) in Acute Leukemia
Author:
- The UCLA Bone Marrow Transplantation GroupTGThe UCLA Bone Marrow Transplantation Group
- 1 February 1977
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 86 (2) , 155-161
Abstract
Fifteen patients with acute leukemia resistant to standard chemotherapy were treated by bone marrow transplantation from HLA-matched siblings after conditioning with a new combination chemotherapy/radiation therapy regimen--SCARI. SCARI consists of 5 days of high-dose cytosine arabinoside and 6-thioguanine followed by 3 days of daunorubicin. After a rest period, cyclophosphamide and total-body irradiation are given sequentially. This regimen had acceptable morbidity. Median survival was 169 days. Overall survival and disease-free survival was 27% at over 11 months. Relapse rate was 13% of the entire group and 30% by actuarial projection. Relapses were late and initially extramedullary. Deaths from causes other than leukemia occurred early secondary to fungal infection and late secondary to interstitial pneumonia (frequently cytomegalovirus). Graft-versus-host disease and graft rejection were not causes of mortality. In these patients conditioned with SCARI, leukemic recurrences were infrequent but infectious complications were a major hazard.Keywords
This publication has 5 references indexed in Scilit:
- Successful bone marrow transplantation against mixed lymphocyte culture barrierBlood, 1976
- Bone-Marrow TransplantationNew England Journal of Medicine, 1975
- Cytomegalovirus Pneumonia After Human Marrow TransplantationAnnals of Internal Medicine, 1975
- Infectious Complications in Patients with Combined Immunodeficiency Diseases Receiving Bone Marrow TransplantsScandinavian Journal of Infectious Diseases, 1974
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958